FindTrial
Sign In

LncRNA WDFY3-AS2 suppresses tumor progression by acting as a ceRNA of microRNA-18a in ovarian cancer

LncRNA WDFY3-AS2 suppresses tumor progression by acting as a ceRNA of microRNA-18a in ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023783
Enrollment
Unknown
Registered
2019-06-11
Start date
2014-01-01
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Case series:Surgery

Sponsors

the Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
27 Years to 60 Years

Inclusion criteria

Inclusion criteria: The surgically resected specimens (30 cases) from the Second Affiliated Hospital of Harbin Medical University from 2014 to 2016 were collected and confirmed by pathological examination as OC

Exclusion criteria

Exclusion criteria: (1) the patients had a history of other malignancies; (2) the patients had severe concurrent infections; (3) the patients had severe concurrent cognitive impairment; (4) the patients had poor adherence or inability to understand the research process.

Design outcomes

Primary

MeasureTime frame
LncRNA WDFY3-AS2 mRNA expression;—

Countries

China

Contacts

Public ContactWenhua Tan

the Second Affiliated Hospital of Harbin Medical University

tan_tanwenhua@yeah.net+86 0451 86662962

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026